Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Status: Recruiting
Diagnosis: Gastrointestinal Malignancies
NCT ID: NCT02026063 (View complete trial on
DFCI Protocol ID: 14-087


The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.


Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Matthew Kulke, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Dana-Farber Cancer Institute: Gastrointestinal Research Line, 617-632-5960

Eligibility Criteria

Inclusion Criteria: - Ongoing participation in a Phase 2 (LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3 (LX1606.1-301-CS, LX1606.1-303-CS) study - Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of <1% per year) during the study and for 12 weeks after the Follow-up visit. - Ability and willingness to provide written informed consent Exclusion Criteria: - Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study - Positive pregnancy test - Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Request Appointment Online